HMA Persistence and Effectiveness in Higher Risk MDS

EP: 1.Advances in MDS Classification and Molecular Understanding

EP: 2.Choosing MDS Therapies: Risk-Based Approaches

EP: 3.Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP: 4.ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP: 5.Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

Now Viewing

EP: 6.HMA Persistence and Effectiveness in Higher Risk MDS

EP: 7.Innovations and Future Directions in Higher Risk MDS Treatments

EP: 8.Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP: 9.Oral vs. IV HMAs: Considerations and Patient Guidance

EP: 10.Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?

• Please include a discussion of 65th American Society of Hematology Annual Meeting and Exposition abstract 548 by Zeidan et al.